Kymera Therapeutics (KYMR) Appoints Leigh Morgan to its Board
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Supermicro probe finds no senior management link to export violations
- SpaceX shares fall as second lockup period ends
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
Kymera Therapeutics Strengthens Board of Directors with Appointment of People and Business Leader Leigh Morgan
July 8, 2022 7:30 AM EDTWATERTOWN, Mass., July 08, 2022 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced the appointment of Leigh Morgan to its Board of Directors. Ms. Morgan joins Kymeras Board as a senior executive accomplished in scaling global, profitable, high-performing organizations.
Leigh has distinguished herself as an expert in developing world-class organizations in a wide variety of settings, and Im thrilled to welcome her to Kymeras Board of Directors, said Nello Mainolfi, PhD, Co-Founder, President and Chief... More
